Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Leukemia, Myeloid, Acute 4Squamous Cell Carcinoma of Head and Neck 1Neoplasms 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Carcinoma, Squamous Cell 1Anemia, Refractory, with Excess of Blasts 1Allogeneic Stem Cell Transplantation 1

Interventions

Cisplatin 14pembrolizumab 8Radiotherapy 7Nivolumab 7Radiotherapy, Intensity-Modulated 5Cetuximab 5Carboplatin 5Fluorouracil 4durvalumab 3Radiosurgery 3Magnetic Resonance Spectroscopy 3Docetaxel 3fluoromisonidazole 2epacadostat 2Standard of Care 2Specimen Handling 2Photochemotherapy 2Paclitaxel 2Drug Therapy 2Cyclophosphamide 2Chemotherapy, Adjuvant 2Capecitabine 2C188-9 compound 2zimberelimab 1yeast-CEA vaccine 1vandetanib 1temoporfin 1talazoparib 1ruxolitinib 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Squamous Cell Carcinoma of Head and Neck × decitabine and cedazuridine drug combination × Clear all
NCT06357858 2024-07-03

ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck

Case Comprehensive Cancer Center

Phase 1 Withdrawn
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡